Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil

Imagem de Miniatura
Arquivos
art_VICTOR_Safety_and_Effectiveness_of_Chemotherapy_for_Metastatic_Esophageal_2019.PDF (788.51 KB)
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER SOC CLINICAL ONCOLOGY
Autores
Citação
JOURNAL OF GLOBAL ONCOLOGY, v.5, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
PURPOSE Despite epidemiologic and molecular differences between esophageal and stomach cancers, most published studies have included patients with either disease in a metastatic scenario. We evaluated the safety and effectiveness of chemotherapy in patients with metastatic esophageal cancer in the community setting. PATIENTS AND METHODS We performed a retrospective cohort study of patients with synchronous metastatic esophageal cancer treated at a public hospital between 2008 and 2016. Patients were grouped according to a prescribed chemotherapy protocol: platinum and taxane (group A); platinum and irinotecan (group B); platinum and fluoropyrimidine (group C); and without platinum (group D). RESULTS Of the 1,789 patients with esophageal cancer treated, we included 397 with metastatic disease at presentation. Squamous cell carcinoma was the most frequent histology (78.8%). Median overall survival (OS) was 7 months (95% CI, 6.15 to 7.85 months). Chemotherapy was administered to 285 patients, who reached a median OS of 9.0 months (95% CI, 8.0 to 9.9 months); for 112 patients who did not receive treatment, median OS was 3 months (95% CI, 2.3 to 3.7 months; P < .001). The most used combination was platinum plus irinotecan (A; 55.5%). Disease control with in groups A, B, C, and D was 39.2%, 30.1%, 53% and 14.3%, respectively. Patients in group C reached a median OS of 17 months (95% CI, 13.1 to 20.8 months; P = .034). No differences were observed in median OS obtained with other protocols (9 months). The toxicity profile was different according to chemotherapy, with more severe events (hematologic, diarrhea, and number of days hospitalized) occurring in group B. CONCLUSION Platinum plus paclitaxel or platinum plus irinotecan provided similar OS in community patients, although patients receiving irinotecan experienced more severe events. In the adenocarcinoma population, a fluoropyrimidine plus platinum-based regimen, although less frequently used, had a more favorable toxicity profile, with superior median OS and disease control. J Global Oncol. (C) 2019 by American Society of Clinical Oncology
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/33671
Referências
  1. Adenis A, 2010, ONCOLOGY-BASEL, V79, P46, DOI 10.1159/000318029
  2. Bang YJ, 2010, LANCET, V376, P1302
  3. Barrios E, 2016, CANCER EPIDEMIOL, V44, pS53, DOI 10.1016/j.canep.2016.03.013
  4. Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
  5. Bleiberg H, 1997, EUR J CANCER, V33, P1216, DOI 10.1016/S0959-8049(97)00088-9
  6. Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
  7. Castellsague X, 1999, INT J CANCER, V82, P657, DOI 10.1002/(SICI)1097-0215(19990827)82:5<657::AID-IJC7>3.0.CO;2-C
  8. Cohen DJ, 2015, J CLIN ONCOL, V33, P1754, DOI 10.1200/JCO.2014.59.7765
  9. Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
  10. El-Rayes BF, 2004, ANN ONCOL, V15, P960, DOI 10.1093/annonc/mdh230
  11. Enzinger PC, 2016, J CLIN ONCOL, V34, P2736, DOI 10.1200/JCO.2015.65.5092
  12. Hiramoto S, 2018, INT J CLIN ONCOL, V23, P466, DOI 10.1007/s10147-018-1239-x
  13. Ilson DH, 1998, J CLIN ONCOL, V16, P1826, DOI 10.1200/JCO.1998.16.5.1826
  14. Ilson DH, 2000, CANCER J, V6, P316
  15. Ilson DH, 1999, J CLIN ONCOL, V17, P3270, DOI 10.1200/JCO.1999.17.10.3270
  16. Janmaat VT, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004063.pub4
  17. Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805
  18. Kim M, 2017, CANCER RES TREAT, V49, P416, DOI 10.4143/crt.2016.121
  19. Kitagawa R, 2015, J CLIN ONCOL, V33, P2129, DOI 10.1200/JCO.2014.58.4391
  20. Liu Y, 2016, AM J CANCER RES, V6, P2345
  21. Lordick F, 2016, ANN ONCOL, V27, pv50, DOI 10.1093/annonc/mdw329
  22. Lubin JH, 2014, CANCER EPIDEM BIOMAR, V23, P107, DOI 10.1158/1055-9965.EPI-13-0796
  23. Prithviraj GK, 2015, DIS ESOPHAGUS, V28, P782, DOI 10.1111/dote.12279
  24. Rao S, 2018, ANN ONCOL, V29
  25. Smyth EC, 2016, ANN ONCOL, V27, pv38, DOI 10.1093/annonc/mdw350
  26. Tustumi F, 2016, ABCD-ARQ BRAS CIR DI, V29, P138, DOI 10.1590/0102-6720201600030003
  27. Urba SG, 2004, INVEST NEW DRUG, V22, P91, DOI 10.1023/B:DRUG.0000006179.20974.af

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03